Kymos Pharma, a Contract Research Organisation (CRO) and member of CataloniaBio & HealthTech, has bought German company Prolytic GmbH in order to strengthen its activity in the biologics and advanced therapies market. The company previously acquired Italian firm Pharmaprogress in 2016.
"This strategic merger gives us the opportunity to increase our service offering, strengthen the emerging therapies market and create a multinational and multidisciplinary company. We are very much looking forward to this new phase in the company’s history", says Joan Puig de Dou, co-founder and CEO of Kymos Pharma.
From now on, Kymos' services will be for innovative small and large molecules, generics, biosimilars, antibodies, biomarkers, ADA (anti-drug antibodies), ADC (antibody-drug conjugates), hormones, enzymes and nucleic acids.
Founded in 2001 with headquarters in Barcelona, Kymos has 110 employees plus the additional 40 on staff at Pharmaprogress and Prolytic. The joint turnover of the three companies is expected to exceed €13 million in 2020.
Joan Puig de Dou was a member of CataloniaBio Board of Directors from 2014 to 2018 (currently CataloniaBio & HealthTech).
Photo: Joan Puig de Dou, CEO of Kymos, and Dorothee Krone, managing director of Prolytic - © Kymos Pharma
You also may be interested in:
Comments